Clinical trials · Washington, D.C., DC
Neoplasms clinical trials in Washington, D.C.
We’re tracking 174 recruiting neoplasms studies with a site in or near Washington, D.C. — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT02346435Recruiting
Watch small kidney growths, with added follow-up later
This registry follows people who have a small kidney mass found by chance on recent scans. It helps doctors understand the best timing for monitoring and possible treatment, to improve safety and outcomes.
Baltimore, MarylandAges 18–100 - NCT03968406RecruitingPhase 1
Talazoparib plus radiation for recurrent gynecologic cancers
This Phase 1 study tests whether the cancer drug talazoparib, combined with radiation, can better control recurrent gynecologic cancers in the pelvis/abdomen. It focuses on patients whose cancer has come back locally enough that radiation can be given, while other disease is not rapidly worsening.
Baltimore, MarylandAges 18 years+ - NCT07441694RecruitingPhase 1
Study of INCA036978 for blood cancers
This trial tests a new drug called INCA036978 for people with a group of blood cancers called myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia. It aims to see if the drug is safe and works well.
Baltimore, MarylandAges 18 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Baltimore, MarylandAges Any age - NCT00288119Recruiting
Study genes in Barrett’s esophagus and esophageal cancer
This study looks at genetic (inherited) factors that may be linked to Barrett’s esophagus and esophageal cancer. It may help researchers understand why these conditions happen in some families and others do not.
Baltimore, MarylandAges 18 years+ - NCT06482515RecruitingPhase 2
Meal timing for fatigue after blood cancer treatment
This study tests whether timing your meals in a certain way can help reduce fatigue in people who have finished treatment for a blood cancer. If you're still struggling with tiredness, this may offer a practical, non-drug approach to feel better.
Baltimore, MarylandAges 18 years+ - NCT07360119Recruiting
Pancreas removal with islet transplant for high-risk tumors
This trial removes the whole pancreas in people with certain pancreatic tumors and then transplants the patient's own insulin-making cells (islets) into the liver. The goal is to prevent or reduce diabetes after surgery.
Baltimore, MarylandAges 18 years+ - NCT05882058RecruitingPhase 2
Dose test of a DLL3 cancer drug for neuroendocrine tumors
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
Baltimore, MarylandAges 18 years+ - NCT04473794Recruiting
Testing ways to assess pancreatic cyst risk and progression
This study looks at patients who have been referred for evaluation of a pancreatic cyst. It aims to improve how doctors estimate risk and predict how cysts may change over time.
Baltimore, MarylandAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Baltimore, MarylandAges 18 years+ - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
Baltimore, MarylandAges 18 years+ - NCT06034002RecruitingPhase 1
Study of INCA033989 for myeloproliferative neoplasms
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
Baltimore, MarylandAges 18 years+ - NCT07008118RecruitingPhase 1
Study of INCA035784 for certain blood cancers
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
Baltimore, MarylandAges 18 years+ - NCT04489719Recruiting
Testing whether DNA repair changes affect radium-223 response
This study looks at whether differences in a cancer’s DNA repair system can predict how well radium-223 works for men with prostate cancer that has spread to the bones. It may help researchers choose better treatment for people with bone metastatic, castration-resistant prostate cancer.
Baltimore, MarylandAges 18 years+ - NCT06966700RecruitingPhase 3
Study of Sac-TMT in Early High-Risk Breast Cancer
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT07216521Recruiting
Study of why surgery was done for an IPMN cyst
This study looks at why doctors decided to do surgery for a certain type of pancreatic cyst (IPMN) and how well patients did after. If you had surgery for an IPMN between 2015 and 2025, you may be able to help doctors learn more.
Baltimore, MarylandAges 18 years+ - NCT06486454Recruiting
Liver tumor treatment with sound waves
This trial tests a new device that uses sound waves to destroy liver tumors without cutting or needles. It may be an option if you have a liver tumor that can be partly or fully targeted by this technique.
Baltimore, MarylandAges 22 years+ - NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
Baltimore, MarylandAges 18 years+ - NCT07071155RecruitingEarly Phase 1
Momelotinib with a hypomethylating agent for certain blood cancers
This trial tests a combination of two drugs, momelotinib and a hypomethylating agent, for people with certain slow-growing blood cancers. If you have a diagnosis like chronic myelomonocytic leukemia or chronic neutrophilic leukemia and have an enlarged spleen, this study might be exploring a new treatment option for you.
Baltimore, MarylandAges 18–100 - NCT05617716RecruitingPhase 2
Spine radiosurgery for painful cancer spread to the spine
This Phase 2 study tests a precise radiation treatment (spine SBRT, also called radiosurgery) to reduce pain from cancer that has spread to the spine. It focuses on people with stable spine structure and low pain at the start, to see how well the treatment works and stays safe.
Baltimore, MarylandAges 18 years+ - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Baltimore, MarylandAges 18 years+ - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Baltimore, MarylandAges 18 years+ - NCT05711667RecruitingPhase 3
Letermovir to prevent CMV after stem cell transplant in kids
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Baltimore, MarylandAges 2–18 - NCT07412002Recruiting
End-of-life care quality for children with cancer
This trial asks bereaved parents about the quality of care their child received in the last month of life. It aims to improve how hospitals support families when a child with cancer is dying.
Baltimore, MarylandAges 18 years+
Hear when a new Neoplasms trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Neoplasms trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting neoplasms studies listed above.
- Johns Hopkins University · 13 studies
- Sinai Hospital of Baltimore · 3 studies
- Johns Hopkins Hospital · 2 studies
- University of Maryland, Baltimore · 2 studies
- Greater Baltimore Medical Center
- Johns Hopkins University Hospitals
- Local Institution - 1035
- Mercy Medical Center - Baltimore
What taking part in a neoplasms study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting neoplasms studies in District of Columbia.
Common questions
- Are there neoplasms clinical trials near Washington, D.C.?
- Yes. We're currently tracking 174 recruiting neoplasms studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neoplasms study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neoplasms studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.